CN107427550B - 细胞穿透抗体 - Google Patents

细胞穿透抗体 Download PDF

Info

Publication number
CN107427550B
CN107427550B CN201680015852.5A CN201680015852A CN107427550B CN 107427550 B CN107427550 B CN 107427550B CN 201680015852 A CN201680015852 A CN 201680015852A CN 107427550 B CN107427550 B CN 107427550B
Authority
CN
China
Prior art keywords
cell penetrating
biotin
protein
conjugate
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680015852.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107427550A (zh
Inventor
A·赫尔曼
H·于
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Priority to CN202111067358.2A priority Critical patent/CN113797349A/zh
Publication of CN107427550A publication Critical patent/CN107427550A/zh
Application granted granted Critical
Publication of CN107427550B publication Critical patent/CN107427550B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680015852.5A 2015-01-16 2016-01-15 细胞穿透抗体 Active CN107427550B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111067358.2A CN113797349A (zh) 2015-01-16 2016-01-15 细胞穿透抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562104653P 2015-01-16 2015-01-16
US62/104,653 2015-01-16
PCT/US2016/013668 WO2016115500A1 (en) 2015-01-16 2016-01-15 Cell penetrating antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111067358.2A Division CN113797349A (zh) 2015-01-16 2016-01-15 细胞穿透抗体

Publications (2)

Publication Number Publication Date
CN107427550A CN107427550A (zh) 2017-12-01
CN107427550B true CN107427550B (zh) 2021-10-08

Family

ID=56406478

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680015852.5A Active CN107427550B (zh) 2015-01-16 2016-01-15 细胞穿透抗体
CN202111067358.2A Pending CN113797349A (zh) 2015-01-16 2016-01-15 细胞穿透抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111067358.2A Pending CN113797349A (zh) 2015-01-16 2016-01-15 细胞穿透抗体

Country Status (18)

Country Link
US (1) US11730789B2 (https=)
EP (2) EP3244910B1 (https=)
JP (2) JP7260248B2 (https=)
KR (1) KR20170098957A (https=)
CN (2) CN107427550B (https=)
AR (1) AR103428A1 (https=)
AU (2) AU2016206475B2 (https=)
BR (1) BR112017015203A2 (https=)
CA (1) CA2972986A1 (https=)
EA (1) EA201791610A1 (https=)
IL (1) IL253403A0 (https=)
MX (2) MX386621B (https=)
PH (1) PH12017501271A1 (https=)
SG (1) SG11201705413WA (https=)
TW (1) TW201632207A (https=)
UY (1) UY36519A (https=)
WO (1) WO2016115500A1 (https=)
ZA (2) ZA201705120B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36519A (es) * 2015-01-16 2016-08-31 Hope City Anticuerpos de penetración celular
JP6752231B2 (ja) 2015-06-01 2020-09-09 カリフォルニア インスティテュート オブ テクノロジー 抗原を用いて特異的集団に関してｔ細胞をスクリーニングするための組成物および方法
EP3331543A4 (en) * 2015-08-06 2019-03-20 City of Hope Cell-pollenizing protein antibody conjugates and methods of use
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
WO2018165475A1 (en) 2017-03-08 2018-09-13 California Institute Of Technology Pairing antigen specificity of a t cell with t cell receptor sequences
JP7295838B2 (ja) * 2017-07-13 2023-06-21 シティ・オブ・ホープ ホスホロチオエートコンジュゲートペプチド及びその使用方法
EP3730150A4 (en) * 2017-12-22 2021-10-06 Rophibio, Inc. ANTI-STAT3 BISPECIFIC ANTIBODY WITH CELL-PENETRATING ABILITY AND THIS PHARMACEUTICAL COMPOSITION
CN119405832A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
KR102075724B1 (ko) 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도
WO2021226107A1 (en) * 2020-05-05 2021-11-11 Avidity Biosciences, Inc. Compositions and methods of treating pompe disease
US20230321250A1 (en) * 2020-07-08 2023-10-12 Octagon Therapeutics, Inc. Cancer cell modulators
KR102739776B1 (ko) 2020-10-26 2024-12-09 한국원자력의학원 로자탄을 유효성분으로 포함하는 항암제의 종양 침투력 증진용 조성물 및 이의 용도
EP4634373A1 (en) 2022-12-16 2025-10-22 University of Rochester Repairment of barrier dysfunction in esophagus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586708B2 (en) * 2005-10-28 2013-11-19 Massachusetts Institute Of Technology Monovalent streptavidin compositions

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
WO2004005476A2 (en) * 2002-07-03 2004-01-15 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CA2825762A1 (en) * 2005-08-31 2007-03-08 Oncolytics Biotech Inc. Method for enhancing anti-neoplastic activity of an oncolytic virus using modified dendritic cells
AU2006325030B2 (en) 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
US20100239504A1 (en) * 2007-07-17 2010-09-23 The General Hospital Corporation Imaging nucleic acid binding proteins
US20110218334A1 (en) * 2008-07-11 2011-09-08 Alnylam Pharmaceuticals, Inc. PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
US20110251258A1 (en) 2008-07-24 2011-10-13 Rxi Pharmaceuticals Corporation Rnai constructs and uses thereof
CN105658230B (zh) * 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法
UY36519A (es) * 2015-01-16 2016-08-31 Hope City Anticuerpos de penetración celular
US10758624B2 (en) 2015-07-02 2020-09-01 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
EP3331573A4 (en) * 2015-08-06 2019-02-27 City of Hope THERAPEUTIC CELL-INTERNALIZING CONJUGATES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586708B2 (en) * 2005-10-28 2013-11-19 Massachusetts Institute Of Technology Monovalent streptavidin compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer’s Disease and Cerebral AIDS;RUBEN J. BOADO等;《Journal of Pharmaceutical Sciences》;19980825;第87卷(第11期);图2 *

Also Published As

Publication number Publication date
UY36519A (es) 2016-08-31
MX2017009272A (es) 2018-04-11
TW201632207A (zh) 2016-09-16
EP3244910A1 (en) 2017-11-22
CA2972986A1 (en) 2016-07-21
ZA201705120B (en) 2022-02-23
JP2021152022A (ja) 2021-09-30
EA201791610A1 (ru) 2017-12-29
PH12017501271A1 (en) 2018-02-05
MX2021011584A (es) 2021-10-13
AU2016206475A1 (en) 2017-07-20
IL253403A0 (en) 2017-09-28
JP2018505870A (ja) 2018-03-01
CN107427550A (zh) 2017-12-01
AR103428A1 (es) 2017-05-10
BR112017015203A2 (pt) 2018-03-13
ZA202105220B (en) 2023-01-25
JP7260248B2 (ja) 2023-04-18
US11730789B2 (en) 2023-08-22
KR20170098957A (ko) 2017-08-30
SG11201705413WA (en) 2017-08-30
US20180008667A1 (en) 2018-01-11
AU2022200592A1 (en) 2022-02-24
MX386621B (es) 2025-03-19
WO2016115500A1 (en) 2016-07-21
AU2016206475B2 (en) 2021-11-04
EP3244910B1 (en) 2020-09-16
EP3244910A4 (en) 2018-08-08
CN113797349A (zh) 2021-12-17
EP3795168A1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
CN107427550B (zh) 细胞穿透抗体
CN108135958B (zh) 细胞穿透蛋白-抗体缀合物及其使用方法
CN105658230B (zh) 细胞穿透缀合物及其使用方法
CN108136042A (zh) 治疗性细胞内化缀合物
CN107074940A (zh) 针对agr2和其受体c4.4a的阻断性单克隆抗体
US20130295581A1 (en) Methods and Compositions for the Treatment and Diagnosis of Breast Cancer
CN104334195A (zh) 包含抑制scf或者其受体的物质的用于治疗或预防血管渗透性相关疾病的组合物
CN108603037B (zh) 细胞穿透花青偶联抗体
CN111139299B (zh) Josd2蛋白在制备治疗恶性肿瘤药物中的应用
HK40049872A (en) Cell penetrating antibodies
KR20200118931A (ko) 저산소 환경에서 유발되는 암의 전이 억제용 조성물
CN115867315A (zh) 用于抑制细胞外囊泡的分泌的细胞外囊泡分泌抑制剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant